Chronicling the COPD Patient Journey and Change in COPD Symptoms, Quality of Life and Exacerbations Following Initiation of Budenoside/Glycopyrronium/Formoterol [BGF]

Inclusion Criteria: * Physician diagnosis of COPD * COPD patients in the Best Care Network who have a CAT score \>=10 * Age \>=35 at time of enrolment * Minimum 12-month recorded prior medical history for patients * Physician decision and patient agreement to initiate treatment with Breztri based on routine care (and in accordance with label and reimbursement criteria) * Ability to read English and to provide consent to inclusion in the study Exclusion Criteria: * Diagnosis of asthma * Dementia or other health issues related to memory * Inability to use inhalers * COPD due to documented α-1 antitrypsin deficiency * Previous treatment with triple fixed-dose combination therapy in 12 months prior to screening visit * Hospitalisation due to COPD exacerbation within the last 30 days prior to enrolment * Pregnancy or lactation period * Participation in an ongoing clinical interventional or observational trial for another COPD medication (or completed another trial within last 30 days of initiating BGF) * Patient self-reporting or a physician record with an active COVID-19 infection at time of enrolment or hospitalized due to COVID-19 infection in the last 60 days * Previous enrolment in this study